Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 10, 2017− Preliminary Data Show that Eltanexor is Well Tolerated and Demonstrates Promising Activity in Multiple Myeloma —
NEWTON, Mass., Dec. 10, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the presentation of Phase 1/2 clinical data...
-
Nov 13, 2017
NEWTON, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief...
-
Nov 7, 2017− Recent Utilization of ATM Financing Facility Nets Proceeds of $47 million; Extends Cash Runway to end of 2018, Beyond STORM Expansion Data Readout —
NEWTON, Mass., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the third quarter 2016...
-
Nov 3, 2017
NEWTON, Mass., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief...
-
Nov 2, 2017− Company Completes Exclusive Licensing Transaction Valued at Up To $193 Million Plus Royalties with Ono Pharmaceutical Co. Ltd. for Selinexor and KPT-8602 In Japan and Certain Other Countries in Asia —
NEWTON, Mass., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the third quarter 2017...